Evaluation of a hydrophobic gel adhering to the gingiva in comparison with a
standard water-soluble 1% chlorhexidine gel after scaling and root planing in
patients with moderate chronic periodontitis. A randomized clinical trial.
Author(s): Rusu D(1), Stratul SI(1), Sarbu C(1), Roman A(2), Anghel A(3), Didilescu A(4),
Jentsch H(5).
Affiliation(s): Author information:
(1)Department of Periodontology, Victor Babes University of Medicine and
Pharmacy, Timisoara, Romania. (2)Department of Periodontology, Iuliu Hatieganu
University of Medicine and Pharmacy, Cluj-Napoca, Romania. (3)Department of
Biochemistry, Victor Babes University of Medicine and Pharmacy, Timisoara,
Romania. (4)Department of Embryology, Carol Davila University of Medicine and
Pharmacy, Bucharest, Romania. (5)Centre for Periodontology, Department of
Conservative Dentistry and Periodontology, University of Leipzig, Leipzig,
Germany.
Publication date & source: 2015, Int J Dent Hyg. ,
OBJECTIVES: To evaluate the clinical, microbiological and enzymatic activity of a
hydrophobic chlorhexidine-based gingiva-adhering gel containing herbal
ingredients, compared with a commercially available 1% chlorhexidine
water-soluble gel, during non-surgical therapy of moderate chronic periodontitis.
METHODS: A total of 34 subjects participated in this 6-month blinded randomized
parallel controlled trial (ISRCTN35210084). After scaling and root planing (SRP),
test group received the gel, by rubbing on the gingiva, once every second day,
for 14 days. The control group received the control gel twice daily. Clinical
parameters considered were the approximal plaque index, simplified oral hygiene
index, modified gingival index, bleeding on probing, probing depth and clinical
attachment level (primary outcome), assessed at baseline, 3 and 6 months,
together with the frequency of detection of Aggregatibacter
actinomycetemcomitans, Porphyromonas gingivalis (P.g.), Prevotella intermedia,
Treponema denticola (T.d.), Tannerella forsythia (T.f.), and activity of
neutrophil elastase and myeloperoxidase (secondary outcomes).
RESULTS: At 3 and 6 months, all clinical parameters improved significantly,
without significant intergroup differences, except OHI-S, which improved at
3 months (P < 0.05). Microbiological data resulted in no significant intergroup
differences at baseline and 6 months. At 3 months, significant differences for
P.g., T.f. and T.d. were noted. A significant reduction of neutrophil elastase
after 3 and 6 months was observed (P < 0.005), without significant intergroup
differences. For myeloperoxidase, significant reductions were noted in both
groups (P < 0.005 and P < 0.05), but no significant intergroup differences. The
tested product seemed to have an increased efficacy, due to longer persistence on
the gingiva, with reduced application frequency.
CONCLUSIONS: Both products had a relatively similar influence on the clinical,
microbiological and enzymatic outcomes at 3 and 6 months after SRP.
|